Volume 133, Issue 10



March 7, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review Series: Myelodysplastic Syndromes. See the articles in the series.

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
In a plenary paper, Burger et al report that although rituximab added to ibrutinib results in faster and deeper remissions, it fails to improve progression-free survival in patients with chronic lymphocytic leukemia.

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
Opstal-van Winden and colleagues perform single nucleotide polymorphism analysis to identify a polygenic risk score that is predictive of the development of breast cancer following radiotherapy for Hodgkin lymphoma.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
Christen et al report on whole exome sequencing on over 300 patients with t(8;21) acute myeloid leukemia, including 19 matched samples at diagnosis, remission, and relapse, to define the genomic landscape or the disease and to identify alleles associated with risk of relapse.

A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain
Most patients with hereditary angioedema have defects in the activity of a C1-esterase inhibitor, but a minority have been linked to a mutation in the factor XII (FXII) gene. Ivanov and colleagues demonstrate that FXII with Lys/Arg309 has increased ability for reciprocal activation of prekallikrein, leading to increased bradykinin activity and angioedema.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials


Introduction to a review series on myelodysplastic syndromes
This Review Series on Myelodysplastic Syndromes presents the range of new insights into the genetics, pathogenesis, and treatment of this heterogeneous and challenging disease. In the same issue, a Special Report offers proposals for a revision of the hematologic response criteria for patients in clinical trials for myelodysplastic syndromes.

The articles in this review series include the following:

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.